X4 Pharmaceuticals Inc (XFOR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $318.59M
Last updated: Nov 17, 2026 at 11:05 AM ET
X4 Pharmaceuticals Inc (XFOR) Competitors
The companies most similar to X4 Pharmaceuticals are Fulcrum Therapeutics (FULC), Phathom Pharmaceuticals (PHAT) and Bicycle Therapeutics (BCYC). By market cap, X4 Pharmaceuticals ranks 8th of the 13 companies on this page; Phathom Pharmaceuticals (PHAT) is the largest at $492.63M.
Peer Comparison
XFOR's ROIC of -36.9% is below the peer median of -2.3%, and its revenue growth of 63.1% is above the median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| X4 Pharmaceuticals (XFOR) | $318.59M | N/A | 21.7x | 0.0% | -36.9% | 63.1% | 0.00% |
| Fulcrum Therapeutics Inc (FULC) | $287.96M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Phathom Pharmaceuticals Inc (PHAT) | $492.63M | N/A | 1.8x | -30.2% | 11.4% | 71.1% | 0.00% |
| Bicycle Therapeutics Ltd (BCYC) | $236.22M | N/A | 2.7x | -169.8% | N/A | 190.2% | 0.00% |
| Rocket Pharmaceuticals Inc (RCKT) | $256.82M | N/A | N/A | 0.0% | -2.3% | 0.0% | 0.00% |
| Shattuck Labs Inc (STTK) | $473.57M | N/A | N/A | 0.0% | N/A | -66.6% | 0.00% |
| Bright Minds Biosciences Inc (DRUG) | $227.96M | N/A | N/A | 0.0% | -11.2% | 0.0% | 0.00% |
| Prothena Corporation plc (PRTA) | $419.01M | N/A | 7.8x | -45.4% | N/A | -74.3% | 0.00% |
| CytomX Therapeutics Inc (CTMX) | $444.73M | N/A | 31.0x | 0.0% | -32.8% | -71.7% | 0.00% |
| Larimar Therapeutics Inc (LRMR) | $313.73M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Rezolute Inc (RZLT) | $353.54M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| CorMedix Inc (CRMD) | $370.64M | 6.3x | 0.9x | 15.5% | 13.9% | -47.7% | 0.00% |
| Fennec Pharmaceuticals Inc (FENC) | $410.25M | 159.5x | 6.8x | 3.0% | N/A | 57.3% | 0.00% |
| Peer median | $362.09M | 82.9x | 4.7x | 0.0% | -2.3% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to X4 Pharmaceuticals, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Fulcrum Therapeutics Inc (FULC) | Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products to improve the lives of patients with genetically defined... | FULC competitors |
| Phathom Pharmaceuticals Inc (PHAT) | Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. | PHAT competitors |
| Bicycle Therapeutics Ltd (BCYC) | Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, is developing a class of drugs for diseases that are not served by existing treatments. | BCYC competitors |
| Rocket Pharmaceuticals Inc (RCKT) | Rocket Pharmaceuticals, Inc., is a cross-platform biotechnology company focused on developing gene therapies for rare and devastating pediatric diseases. | RCKT competitors |
| Shattuck Labs Inc (STTK) | Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapies for the treatment of cancer and autoimmune diseases in the United States. | STTK competitors |
| Bright Minds Biosciences Inc (DRUG) | Bright Minds Biosciences Inc. (DRUG) is a forward-thinking clinical-stage biotechnology firm specializing in the development of groundbreaking therapies... | DRUG competitors |
| Prothena Corporation plc (PRTA) | Prothena Corporation plc, an advanced stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases... | PRTA competitors |
| CytomX Therapeutics Inc (CTMX) | CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States. | CTMX competitors |
| Larimar Therapeutics Inc (LRMR) | Larimar Therapeutics, Inc., a clinical-stage biotechnology company, is focused on developing treatments for rare diseases. | LRMR competitors |
| Rezolute Inc (RZLT) | Rezolute, Inc., a clinical-stage biopharmaceutical company, develops rare and metabolic disease therapies in the United States. | RZLT competitors |
| CorMedix Inc (CRMD) | CorMedix Inc., a biopharmaceutical company, focuses on developing and marketing therapeutic products for the prevention and treatment of infectious... | CRMD competitors |
| Fennec Pharmaceuticals Inc (FENC) | Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops candidate products for use in the treatment of cancer in the United States. | FENC competitors |
Frequently Asked Questions About XFOR
Who are X4 Pharmaceuticals' main competitors?
The companies most similar to X4 Pharmaceuticals include Fulcrum Therapeutics (FULC), Phathom Pharmaceuticals (PHAT), Bicycle Therapeutics (BCYC), Rocket Pharmaceuticals (RCKT) and Shattuck Labs (STTK), listed from the closest match.
Who is X4 Pharmaceuticals' biggest competitor?
Phathom Pharmaceuticals (PHAT) is the largest of the similar companies at $492.63M; Fulcrum Therapeutics (FULC) is the closest match by business profile, size, sector and industry.
How does XFOR stock compare with its competitors?
XFOR's P/S is 21.7x against a peer median of 4.7x; its net margin is 0.0% against a peer median of 0.0%.
Which of X4 Pharmaceuticals' competitors pays a higher dividend?
X4 Pharmaceuticals pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is X4 Pharmaceuticals bigger than its competitors?
No. X4 Pharmaceuticals is 8th by market cap among the 13 companies on this page; the largest is Phathom Pharmaceuticals (PHAT) at $492.63M.
XFOR pages: Overview, Earnings, Forecast, Financials, Competitors